In the weeks since Narendra Modi won the Indian election, drugmakers and other manufacturers have looked expectantly to the new government's first budget. Now, with the budget nearing, manufacturers have opened up about what they want and politicians from the United Kingdom have flown in to unveil Cipla's £100 million ($172 million) investment in the former colonial power.
Pfizer has a manufacturing plant underway in Saudi Arabia that is slated to be operating next year. But the drugmaker has just struck a deal that will give it access to additional capacity, as well as products, in that country.
Parexel International is looking to broaden its presence in the Middle East and North Africa, snapping up Turkish CRO Atlas Medical Services.
Intuitive Surgical is kicking off direct sales of its da Vinci Surgical Systems in Japan, continuing its push in emerging markets and hoping to generate positive numbers after a year of sluggish sales.
India-based Cipla has been expanding its manufacturing footprint outside of its base in India and has now made the jump across the Arabian Sea to Yemen.
Novotech, which bills itself as Australia's largest CRO, has signed a deal with a South Korean outfit to help bolster the country's status among global drug development locales.
A team from the Massachusetts Institute of Technology is a finalist for the 2014 Hult Prize after developing a simple wound-therapy device to improve the lives of those lacking access to adequate medical care.
Roche and Cipla are writing a new chapter in the bitter battles that have been fought by Western drugmakers over their patents in India. They are in mediation over the patent for Roche's blockbuster cancer fighter Tarceva, in what may be the first case to take this route.
Big Pharma's reputation in China has taken a bruising in the last year after an investigation into GlaxoSmithKline's use of bribery to power sales there spilled over to questions into Roche, Novo Nordisk and others. So what's the industry to do to burnish its image and smooth over the situation with authorities? Hire Chinese nationals who can figure out the puzzle box that is Chinese healthcare.
To avoid the fate of some of its competitors that have run afoul of the FDA over loose manufacturing standards, Dr. Reddy's and some other Indian drugmakers have decided it is worth investing hundreds of millions of dollars for new plants and equipment in a country that has traditionally relied on cheap human labor.